Plasma exosome MicroRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: Effect of glycemic control

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages E1681-E1685

  Santovito, Donato ^a,b   De Nardis, Velia ^a   Marcantonio, Pamela ^a   Mandolini, Claudia ^a   Paganelli, Camilla ^a   Vitale, Elita ^a   Buttitta, Fiamma ^a   Bucci, Marco ^a   Mezzetti, Andrea ^a   Consoli, Agostino ^a   Cipollone, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; MICRORNA; MICRORNA 126; MICRORNA 16; MICRORNA 186; MICRORNA 21; MICRORNA 326; MICRORNA LET 7A; MICRORNA LET 7F; MICRORNA LET 7G; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; TRANSCRIPTOME;

ADIPOR 1 GENE; ADIPOR 2 GENE; ADULT; APPL 1 GENE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXOSOME; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; GENETICS; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED;

ADIPONECTIN; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; EXOSOMES; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICRORNAS; MIDDLE AGED; TRANSCRIPTOME;

EID: 84907190421     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3843     Document Type: Article

References (20)

1. FriedmanRC,FarhKK,Burge CB, Bartel DP. Most mammalianmRNAs are conserved targets of microRNAs. Genome Res. 2009;19: 92-105.
2. Santovito D, Mezzetti A, Cipollone F. MicroRNAs and atherosclerosis: New actors for an old movie. Nutr Metab Cardiovasc Dis. 2012;22: 937-943.
3. Egea V, Schober A, Weber C. Circulating miRNAs: Messengers on the move in cardiovascular disease. Thromb Haemost. 2012;108: 590-591.
4. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD, German MS. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes. 2007;56: 2938-2945.
5. Fernandez-Valverde SL, Taft RJ, Mattick JS. MicroRNAs in -cell biology, insulin resistance, diabetes and its complications. Diabetes. 2011;60: 1825-1831.
6. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107: 810-817.
7. Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011;48: 61-69.
8. Rong Y, Bao W, Shan Z, et al. Increased microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PLoS One. 2013;8: E73272.
9. Pescador N, Pérez-Barba M, Ibarra JM, Corbatón A, Martínez- Larrad MT, Serrano-Ríos M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One. 2013;8: E77251.
10. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet. 2010;375: 735-742.
11. NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362: 1477-1490.
12. Cipollone F, Felicioni L, Sarzani R, et al. A unique microRNA signature associated with plaque instability in humans. Stroke. 2011; 42: 2556-2563.
13. American Diabetes Association. Standards of medical care in diabetes- 2013. Diabetes Care. 2013;36(suppl 1): S11-S66.
14. Zhu H, Shyh-Chang N, Segre AV, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147: 81-94.
15. Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42: 579-589.
16. Tang YF, Zhang Y, Li XY, Li C, TianW,Liu L. Expression of miR-31, miR-125b-5p, and miR-326 in the adipogenic differentiation process of adipose-derived stem cells. OMICS. 2009;13: 331-336.
17. Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, Dotta F. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev. 2011;27: 862-866.
18. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7: 941-946.
19. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2009;302: 179-188.
20. Gao H, Fall T, van Dam RM, et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: A Mendelian randomization study. Diabetes. 2013;62: 1338-1344.